BACKGROUND: Pathophysiological models of bipolar disorder postulate that mood dysregulation arises from fronto-limbic dysfunction, marked by reduced prefrontal cortex (PFC) inhibitory control. This might occur due to both disruptions within PFC networks and abnormal inhibition over subcortical structures involved in emotional processing. However, no study has examined global PFC dysconnectivity in bipolar disorder and tested whether regions with within-PFC dysconnectivity also exhibit fronto-limbic connectivity deficits. Furthermore, no study has investigated whether such connectivity disruptions differ for bipolar patients with psychosis history, who might exhibit a more severe clinical course. METHODS: We collected resting-state functional magnetic resonance imaging at 3T in 68 remitted bipolar I patients (34 with psychosis history) and 51 demographically matched healthy participants. We employed a recently developed global brain connectivity method, restricted to PFC (rGBC). We also independently tested connectivity between anatomically defined amygdala and PFC. RESULTS: Bipolar patients exhibited reduced medial prefrontal cortex (mPFC) rGBC, increased amygdala-mPFC connectivity, and reduced connectivity between amygdala and dorsolateral PFC. All effects were driven by psychosis history. Moreover, the magnitude of observed effects was significantly associated with lifetime psychotic symptom severity. CONCLUSIONS: This convergence between rGBC, seed-based amygdala findings, and symptom severity analyses highlights that mPFC, a core emotion regulation region, exhibits both within-PFC dysconnectivity and connectivity abnormalities with limbic structures in bipolar illness. Furthermore, lateral PFC dysconnectivity in patients with psychosis history converges with published work in schizophrenia, indicating possible shared risk factors. Observed dysconnectivity in remitted patients suggests a bipolar trait characteristic and might constitute a risk factor for phasic features of the disorder.
BACKGROUND: Pathophysiological models of bipolar disorder postulate that mood dysregulation arises from fronto-limbic dysfunction, marked by reduced prefrontal cortex (PFC) inhibitory control. This might occur due to both disruptions within PFC networks and abnormal inhibition over subcortical structures involved in emotional processing. However, no study has examined global PFC dysconnectivity in bipolar disorder and tested whether regions with within-PFC dysconnectivity also exhibit fronto-limbic connectivity deficits. Furthermore, no study has investigated whether such connectivity disruptions differ for bipolarpatients with psychosis history, who might exhibit a more severe clinical course. METHODS: We collected resting-state functional magnetic resonance imaging at 3T in 68 remitted bipolar Ipatients (34 with psychosis history) and 51 demographically matched healthy participants. We employed a recently developed global brain connectivity method, restricted to PFC (rGBC). We also independently tested connectivity between anatomically defined amygdala and PFC. RESULTS:Bipolarpatients exhibited reduced medial prefrontal cortex (mPFC) rGBC, increased amygdala-mPFC connectivity, and reduced connectivity between amygdala and dorsolateral PFC. All effects were driven by psychosis history. Moreover, the magnitude of observed effects was significantly associated with lifetime psychotic symptom severity. CONCLUSIONS: This convergence between rGBC, seed-based amygdala findings, and symptom severity analyses highlights that mPFC, a core emotion regulation region, exhibits both within-PFC dysconnectivity and connectivity abnormalities with limbic structures in bipolar illness. Furthermore, lateral PFC dysconnectivity in patients with psychosis history converges with published work in schizophrenia, indicating possible shared risk factors. Observed dysconnectivity in remitted patients suggests a bipolar trait characteristic and might constitute a risk factor for phasic features of the disorder.
Authors: Heather C Strasser; Jessica Lilyestrom; Ebony R Ashby; Nancy A Honeycutt; David J Schretlen; Ann E Pulver; Ramona O Hopkins; J Raymond Depaulo; James B Potash; Barbara Schweizer; Khara O Yates; Elizabeth Kurian; Patrick E Barta; Godfrey D Pearlson Journal: Biol Psychiatry Date: 2005-03-15 Impact factor: 13.382
Authors: Neal R Swerdlow; Susan B Powell; Michelle R Breier; Samantha R Hines; Gregory A Light Journal: Neuropharmacology Date: 2013-06-26 Impact factor: 5.250
Authors: Jeffrey M Spielberg; Erik B Beall; Leslie A Hulvershorn; Murat Altinay; Harish Karne; Amit Anand Journal: Neuropsychopharmacology Date: 2016-06-30 Impact factor: 7.853
Authors: N Carmiol; J M Peralta; L Almasy; J Contreras; A Pacheco; M A Escamilla; E E M Knowles; H Raventós; D C Glahn Journal: Eur Psychiatry Date: 2013-12-08 Impact factor: 5.361
Authors: Franz X Vollenweider; Alan Anticevic; Katrin H Preller; Joshua B Burt; Jie Lisa Ji; Charles H Schleifer; Brendan D Adkinson; Philipp Stämpfli; Erich Seifritz; Grega Repovs; John H Krystal; John D Murray Journal: Elife Date: 2018-10-25 Impact factor: 8.140